ID   UPMM-3
AC   CVCL_C295
SY   UPMM3; Uveal Primary Melanoma with Monosomy-3 3
DR   CLDB; cl7223
DR   cancercelllines; CVCL_C295
DR   Cosmic; 1628401
DR   ICLC; HTL13001
DR   Wikidata; Q54991709
RX   PubMed=19212147;
RX   PubMed=22236444;
RX   PubMed=23849826;
CC   Doubling time: 100 hours (PubMed=19212147).
CC   Karyotypic information: Monosomy of chromosome 3 (PubMed=19212147).
CC   Sequence variation: Mutation; HGNC; HGNC:4390; GNAQ; Simple; p.Gln209Pro (c.626A>C); ClinVar=VCV000375957; Zygosity=Unspecified (PubMed=22236444).
CC   Derived from site: In situ; Eye, uvea; UBERON=UBERON_0001768.
ST   Source(s): ICLC=HTL13001; PubMed=22236444
ST   Amelogenin: X,Y
ST   CSF1PO: 12,13
ST   D13S317: 8,11
ST   D16S539: 12
ST   D21S11: 28,31.2
ST   D5S818: 10,11
ST   D7S820: 8,11
ST   FGA: 19
ST   TH01: 7,9.3
ST   TPOX: 9,10
ST   vWA: 16,17
DI   NCIt; C7712; Uveal melanoma
DI   ORDO; Orphanet_39044; Uveal melanoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   Age unspecified
CA   Cancer cell line
DT   Created: 22-10-12; Last updated: 10-04-25; Version: 19
//
RX   PubMed=19212147; DOI=10.1159/000201566;
RA   Nareyeck G., Zeschnigk M., Bornfeld N., Anastassiou G.;
RT   "Novel cell lines derived by long-term culture of primary uveal
RT   melanomas.";
RL   Ophthalmologica 223:196-201(2009).
//
RX   PubMed=22236444; DOI=10.1111/j.1755-148X.2012.00971.x; PMCID=PMC3288394;
RA   Griewank K.G., Yu X.-X., Khalili J.S., Sozen M.M., Stempke-Hale K.,
RA   Bernatchez C., Wardell S., Bastian B.C., Woodman S.E.;
RT   "Genetic and molecular characterization of uveal melanoma cell
RT   lines.";
RL   Pigment Cell Melanoma Res. 25:182-187(2012).
//
RX   PubMed=23849826; DOI=10.1016/j.ejca.2013.06.011;
RA   Amaro A., Mirisola V., Angelini G., Musso A., Tosetti F.I.,
RA   Esposito A.I., Perri P., Lanza F.B., Nasciuti F., Mosci C., Puzone R.,
RA   Salvi S., Truini M., Poggi A., Pfeffer U.;
RT   "Evidence of epidermal growth factor receptor expression in uveal
RT   melanoma: inhibition of epidermal growth factor-mediated signalling
RT   by gefitinib and cetuximab triggered antibody-dependent cellular
RT   cytotoxicity.";
RL   Eur. J. Cancer 49:3353-3365(2013).
//